Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AtriCure (ATRC) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for AtriCure (ATRC) over the last 17 years, with Q3 2025 value amounting to $12.4 million.

  • AtriCure's Share-based Compensation rose 1987.65% to $12.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.8 million, marking a year-over-year increase of 1138.51%. This contributed to the annual value of $40.4 million for FY2024, which is 1309.06% up from last year.
  • According to the latest figures from Q3 2025, AtriCure's Share-based Compensation is $12.4 million, which was up 1987.65% from $11.4 million recorded in Q2 2025.
  • AtriCure's 5-year Share-based Compensation high stood at $12.4 million for Q3 2025, and its period low was $6.6 million during Q1 2021.
  • In the last 5 years, AtriCure's Share-based Compensation had a median value of $8.8 million in 2023 and averaged $8.8 million.
  • In the last 5 years, AtriCure's Share-based Compensation skyrocketed by 5063.87% in 2021 and then plummeted by 453.64% in 2022.
  • Over the past 5 years, AtriCure's Share-based Compensation (Quarter) stood at $7.5 million in 2021, then dropped by 4.54% to $7.2 million in 2022, then increased by 29.39% to $9.3 million in 2023, then increased by 11.52% to $10.4 million in 2024, then grew by 19.63% to $12.4 million in 2025.
  • Its last three reported values are $12.4 million in Q3 2025, $11.4 million for Q2 2025, and $9.6 million during Q1 2025.